<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427464</url>
  </required_header>
  <id_info>
    <org_study_id>VMDN-003</org_study_id>
    <nct_id>NCT02427464</nct_id>
  </id_info>
  <brief_title>Phase 3 Gene Therapy for Painful Diabetic Neuropathy</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViroMed Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedTech Consultants Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViroMed Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of bilateral intramuscular
      injections of VM202 versus placebo in the treatment of painful diabetic neuropathy.

      A total of 477 subjects will be randomized in a 2:1 ratio to one of two treatment groups:

      Treatment - VM202 - 318 subjects Control - Placebo (VM202 vehicle) - 159 subjects

      Randomization will be stratified by current use of gabapentin and/or pregabalin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral neuropathy is a serious complication of diabetes. This form of neuropathy carries
      a high risk of pain, trophic changes and autonomic dysfunction. Treatment of diabetic
      peripheral neuropathy (DPN) is based on either pathogenetic mechanisms or symptomatic relief.
      A number of clinical trials have established symptomatic treatment but for pathogenetic
      mechanisms, the only proven treatment strategy is strict glycemic control. Clearly, it would
      be desirable to prevent, impede, or reverse the disrupting and often life-threatening
      manifestations of peripheral neuropathy by stimulating growth or regeneration of peripheral
      nerve axons. The results from previous studies suggest that VM202 provides the same magnitude
      of pain relief as reported with pregabalin or gabapentin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the average pain score</measure>
    <time_frame>Baseline to three month follow up</time_frame>
    <description>Subjects complete a Daily Pain and Sleep Interference diary at Screening (following wash-out of prohibited medications), and Day 90</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of at least 50% reduction in average pain score</measure>
    <time_frame>Baseline to three month follow up</time_frame>
    <description>Subjects complete a Daily Pain and Sleep Interference diary at Screening (following wash-out of prohibited medications), and Day 90</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the average pain score</measure>
    <time_frame>Baseline to Six month follow up</time_frame>
    <description>Subjects complete a Daily Pain and Sleep Interference diary at Screening (following wash-out of prohibited medications), Day 90, Day 180</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of at least 50% reduction in average pain score</measure>
    <time_frame>Baseline to Six month follow up</time_frame>
    <description>Subjects complete a Daily Pain and Sleep Interference diary at Screening (following wash-out of prohibited medications), Day 90, and Day 180</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">477</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <condition>Diabetic Neuropathy, Painful</condition>
  <arm_group>
    <arm_group_label>VM202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the VM202 treatment arm will receive the following intramuscular injections in each calf:
Day 0 - 16 injections of 0.5mL of VM202 / calf
Day 14 - 16 injections of 0.5mL of VM202 / calf
Day 90 - 16 injections of 0.5mL of VM202 / calf
Day 104 - 16 injections of 0.5mL of VM202 / calf</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the placebo control group will receive the following intramuscular injections in each calf:
Day 0 - 16 injections of 0.5mL of VM202 vehicle / calf
Day 14 - 16 injections of 0.5mL of VM202 vehicle / calf
Day 90 - 16 injections of 0.5mL of VM202 vehicle / calf
Day 104 - 16 injections of 0.5mL of VM202 vehicle / calf</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>VM202</intervention_name>
    <description>gene therapy</description>
    <arm_group_label>VM202</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years to 75 years;

          2. Documented history of Type I or II diabetes with current treatment control
             (glycosylated hemoglobin A1c of ≤ 10.0% at Screening) and currently on oral medication
             and / or insulin;

          3. No significant changes anticipated in diabetes medication regimen;

          4. No new symptoms associated with diabetes within the last 3 months prior to study
             entry;

          5. Diagnosis of painful diabetic peripheral neuropathy in both lower extremities;

          6. Lower extremity pain for at least 6 months;

          7. Visual analog scale (VAS) score of ≥ 40 mm at Initial Screening (0 mm = no pain - 100
             mm very severe pain);

          8. Symptoms from the Brief Pain Neuropathy Screening (BPNS) is ≤ 5 point difference
             between legs at Initial Screening;

          9. The average daily pain intensity score of the Daily Pain and Sleep Interference Diary
             completed after medication wash-out is ≥ 4 with a standard deviation ≤ 2;

         10. The physical examination component of the Michigan Neuropathy Screening Instrument
             Score (MNSI) is ≥ 3 at Initial Screening;

         11. Subjects on gabapentin (Neurontin), pregabalin (Lyrica), duloxetine (Cymbalta) for
             painful DPN at study entry must be on stable regimen of these treatments for at least
             3 months prior to study entry; and

         12. If female of childbearing potential, negative urine pregnancy test at screening and
             using acceptable method of birth control during the study.

        Exclusion Criteria:

          1. Peripheral neuropathy caused by condition other than diabetes;

          2. Other pain more severe than neuropathic pain that would prevent assessment of DPN;

          3. Progressive or degenerative neurological disorder;

          4. Myopathy;

          5. Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's
             disease);

          6. Active infection;

          7. Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis);

          8. Positive HIV or HTLV at Screening;

          9. Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAb), antibody
             to Hepatitis B surface antigen (IgG and IgM; HBsAb), Hepatitis B surface antigen
             (HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening;

         10. Subjects with known immunosuppression or currently receiving immunosuppressive drugs,
             chemotherapy or radiation therapy;

         11. Stroke or myocardial infarction within last 3 months;

         12. Specific laboratory values at Screening including: Hemoglobin &lt; 8.0 g/dL, WBC &lt; 3,000
             cells per microliter, platelet count &lt;75,000/mm3, Creatinine &gt; 2.0 mg/dL; AST and/or
             ALT &gt; 3 times the upper limit of normal or any other clinically significant lab
             abnormality which in the opinion of the investigator should be exclusionary;

         13. Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that
             preclude standard ophthalmologic examination;

         14. Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) &gt; 200
             mmHg or diastolic BP (DBP) &gt; 110 mmHg at Screening;

         15. Subjects with a recent history (&lt; 5 years) of or new screening finding of malignant
             neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if
             excised and no evidence of recurrence for one year); subjects with family history of
             colon cancer in any first degree relative are excluded unless they have undergone a
             colonoscopy in the last 12 months with negative findings;

         16. Use of the following drugs / therapeutics is PROHIBITED. Subjects may participate in
             the study if they are willing to discontinue use of these drugs / therapeutics 7 days
             prior to starting the 7 Day Daily Pain and Sleep Interference Diary. Subjects must
             refrain from taking these drugs or undergoing these therapies for the duration of the
             study:

               -  skeletal muscle relaxants, opioids, benzodiazepines (except for stable bedtime
                  dose),

               -  capsaicin, local anesthetic creams and patches, isosorbide dinitrate (ISDN)
                  spray,

               -  transcutaneous electrical nerve stimulation (TENS), acupuncture

         17. If not using gabapentin (Neurontin) or pregabalin (Lyrica), subjects must agree not to
             start these drugs for the first 6 months of the study. Subjects on these medications
             at study entry must maintain a stable dose for the first 6 months of the study;

         18. If not using duloxetine (Cymbalta), any antidepressants (e.g. amitriptyline and
             venlafaxine), any other antiepileptics (e.g., valproic acid, carbamazepine,
             vigabatrin), subjects must agree not to start these drugs for the first 6 months of
             the study.

             Subjects on these medications at study entry must maintain a stable dose for the first
             6 months of the study;

         19. Subjects requiring &gt; 81 mg daily of acetylsalicylic acid; subjects may be enrolled if
             willing/able to switch to ≤ 81 mg daily of acetylsalicylic acid or to another
             medication;

         20. Subjects requiring regular COX-2 inhibitor drug(s) or non-specific COX-1/COX-2
             inhibiting drugs, or high dose steroids (except inhaled steroids or ocular steroids);
             subjects may be enrolled if willing/able to undergo medication wash-out prior to the
             first dosing and to refrain from taking these drugs for the first 6 months of the
             study;

         21. Major psychiatric disorder within last 6 months that would interfere with study
             participation;

         22. Body mass index (BMI) &gt; 45 kg/m2 at Screening;

         23. Any lower extremity amputation due to diabetic complications;

         24. Use of an investigational drug or treatment in past 6 months, or prior participation
             in any study of VM202; and

         25. Unable or unwilling to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Kessler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheila Yi</last_name>
    <email>sheila@viromed.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Salonga</last_name>
      <email>jsalonga@azresearchcenter.com</email>
    </contact>
    <investigator>
      <last_name>Joseph S Gimbel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dusty Holderfield</last_name>
      <email>dholderfield@clinicaltrialsinc.com</email>
    </contact>
    <investigator>
      <last_name>Victor Biton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richard S. Cherlin, MD</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khushbu Singh</last_name>
      <email>cherlin.research@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Richard S Cherlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Woodward</last_name>
      <email>swoodward@norcare.net</email>
    </contact>
    <investigator>
      <last_name>Douglas Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby McCray</last_name>
      <email>Shelby@ccr-trials.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Reyzelman, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Research Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Latorre</last_name>
      <email>jlatorre@drkudrow.com</email>
    </contact>
    <investigator>
      <last_name>David Kudrow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lana Norman</last_name>
      <email>lnorman@diabloclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Morimoto</last_name>
      <email>cmorimoto@diabloclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Christiansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern Connecticut, PC</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Fredricksen</last_name>
      <email>efredericksen@anscneuro.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Toothaker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katy Gustasson</last_name>
      <email>katyg@innovativeresearchfl.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Trevino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida McKnight Brain Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Walker, RN, BSN</last_name>
      <email>sally.walker@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>James Wymer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Health College of Med, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marinella Lipinski</last_name>
      <email>Marinella.Lipinski@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Joe Chehade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Pate</last_name>
      <email>lnorman@diabloclinical.com</email>
    </contact>
    <investigator>
      <last_name>Judith L. White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Moore</last_name>
      <email>smoore@crwf.com</email>
    </contact>
    <investigator>
      <last_name>Lon D. Lynn, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>56001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Joslin</last_name>
      <phone>312-503-7504</phone>
    </contact>
    <contact_backup>
      <email>ben.joslin@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Senda Ajroud-Driss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Jenci</last_name>
      <email>njenci@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tina Liu</last_name>
      <email>tliu@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mazen Dimachkie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Solomon</last_name>
      <email>vsolomon1@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Christine N. Sang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Rolandelli</last_name>
      <email>rolan010@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center Department of Neurology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allan Paras</last_name>
      <email>ap3476@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Brannagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates, P.A.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Pate</last_name>
      <email>tpate@raleighneurology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Bowman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martin Foot and Ankle</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Mincer</last_name>
      <email>beth@martinfootandankle.com</email>
    </contact>
    <investigator>
      <last_name>Maria Kasper, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nerve and Muscle Center of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>56001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zinah Rasheed</last_name>
      <email>houneuzinah@msn.com</email>
    </contact>
    <investigator>
      <last_name>Aziz Shaibani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah -Neurology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kami Grant</last_name>
      <email>kami.grant@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cathy Revere</last_name>
      <email>cathy.revere@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gordon Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EVMS (Eastern Virginia Medical School)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Sander</last_name>
      <email>sanderaa@evms.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron I Vinik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Washington Medical Group</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Abbott,, Pharm D.</last_name>
      <email>sabbott@wwmedgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center, Inc.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Aaker, RDN</last_name>
    </contact>
    <investigator>
      <last_name>Leslie Klaff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic</keyword>
  <keyword>neuropathy</keyword>
  <keyword>shooting pain</keyword>
  <keyword>burning pain</keyword>
  <keyword>pins and needles pain</keyword>
  <keyword>foot pain</keyword>
  <keyword>ViroMed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Pain</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

